A 40-year-old white man with bipolar I disorder, neurolepticinduced parkinsonism, and nonmalignant catatonia presented with a 2-day history of worsening fatigue, dyspnea, and nausea. He had been admitted to the psychiatric unit 3 weeks previously for catatonia, where he gradually improved following medication adjustments. Specifically, risperidone was tapered off and replaced by clozapine to minimize extrapyramidal effects. He continued to improve, showing independence both in his activities of daily living and other self-cares. However, amid his progress, he experienced fatigue, dyspnea, and nausea, warranting further evaluation. At the time of the current presentation, he had no known exposures or sick contacts. He had never smoked and had no notable family history of any medical problems.
40-year-old white man with bipolar I disorder, neurolepticinduced parkinsonism, and nonmalignant catatonia presented with a 2-day history of worsening fatigue, dyspnea, and nausea. He had been admitted to the psychiatric unit 3 weeks previously for catatonia, where he gradually improved following medication adjustments. Specifically, risperidone was tapered off and replaced by clozapine to minimize extrapyramidal effects. He continued to improve, showing independence both in his activities of daily living and other self-cares. However, amid his progress, he experienced fatigue, dyspnea, and nausea, warranting further evaluation. At the time of the current presentation, he had no known exposures or sick contacts. He had never smoked and had no notable family history of any medical problems.
Vitals were notable for a temperature of 39. 5 C, heart rate of 121 beats/min, blood pressure of 122/73 mm Hg, respiratory rate of 16 breaths/min, and oxygen saturation of 93% while breathing room air. Physical examination revealed a flushed, inattentive man lying in bed. Notably, he was quite lethargic, which was an acute change compared to his mental state on the previous day. Cardiac examination revealed a regular rhythm with no appreciable jugular venous distention or lower extremity peripheral edema. Pulmonary, abdominal, neurologic, and skin examination findings were within normal limits. Laboratory evaluation yielded the following results (reference ranges provided parenthetically): hemoglobin, 14.4 g/dL (13.2-16.6 g/dL); leukocytes, 13.1 Â . His troponin T level increased from 0.09 ng/dL (<0.04 ng/mL) at initial measurement to 0.2 ng/dL at 3 hours and 0.33 ng/dL at 6 hours. During this time, he reported no chest pain, pressure, or discomfort. Results of urinalysis and blood cultures were unremarkable. Polymerase chain reaction was negative for influenza A and B and respiratory syncytial virus.
Chest radiography revealed no consolidation, pleural effusion, cardiomegaly, or signs of heart failure. Initial electrocardiography (ECG) showed only sinus tachycardia with no ST-T wave abnormalities. Transthoracic echocardiography (TTE) was notable for generalized hypokinesis with a calculated ejection fraction of 43% and normal right ventricular size, function, and pulmonary pressures. No previous echocardiograms were available because the patient had never undergone echocardiography. elevated troponin level, the most important diagnostic consideration is ACS, particularly a noneST-elevation myocardial infarction. Missing this diagnosis is associated with considerable morbidity and potential mortality. Stress-induced cardiomyopathy is a consideration when elevated troponin with wall motion abnormalities is present, most commonly in the apical distribution, and a discordant absence of severe epicardial coronary artery disease is seen on angiography. Notably, stress cardiomyopathy, in this context, remains a diagnosis of exclusion. 1 Myopericarditis is another consideration in view of the patient's elevated troponin level and depressed left ventricular function. In this scenario, pericarditis alone would be a less likely diagnosis because the patient does not meet 2 of the 4 criteria required for the clinical diagnosis of pericarditis. These criteria include pleuritic/sharp chest pain that typically improves with sitting forward, ECG changes (diffuse ST elevation and/or PR depression), detection of a pericardial friction rub on auscultation, and pericardial effusion on cardiac imaging. 2 Myopericarditis remains a diagnostic possibility once ACS has reliably been excluded. With an elevated troponin level and tachycardia, pulmonary embolism could be considered as well. Using the Wells criteria for risk stratification, meeting only one criterion, with tachycardia, puts the patient at low risk for pulmonary embolism. 3 In addition, with troponin elevation, one may expect to see a more substantial component of right ventricular strain on TTE. Myocarditis is a nonspecific entity with a heterogeneous presentation, typically manifesting 1 of 3 clinical patterns: recent-onset heart failure, arrhythmia, and/or chest pain. 4 Diagnostic criteria for myocarditis include ECG changes, fever, elevation of troponin level, and unexplained functional and structural changes in the heart. 5 In the absence of suspected ACS and coronary artery disease, valve disease, congenital heart disease, hyperthyroidism, and hypertensive cardiomyopathy, higher clinical suspicion should be given to this entity. With the patient presenting with new-onset decreased ejection fraction, dyspnea, fever, low suspicion for other cardiac entities, elevated troponin level, and his echocardiographic findings, myocarditis was deemed the most likely diagnosis, after the concern for ACS was ruled out using noninvasive testing with coronary computed tomographic (CT) angiography.
The patient was treated conservatively with acetaminophen, and his fever resolved in about 24 hours. Coronary computed tomographic angiography disclosed absence of obstructive epicardial coronary artery disease. After cardiology consultation, continuous telemetry was initiated in the setting of tachycardia, elevated troponin level, and presumed myocarditis diagnosis. Troponin T values peaked at 0.57 ng/dL over the next 24 hours. All of these etiologies can cause myocarditis. A thorough history and physical examination can narrow the differential diagnosis. Unfortunately, the etiology of the myocarditis is often unknown, with the other typical etiologic distributions being (1) idiopathic, (2) infectious (typically viral), (3) autoimmune, and (4) other. 5 Classically in terms of infection, enteroviruses such as coxsackievirus B and viruses like adenovirus are implicated. In recent years, studies using endomyocardial biopsies along with polymerase chain reaction and serologic testing have found that viruses, such as parvovirus B19, are becoming much more prevalent. 6 In enterovirus infections, patients often present with viral symptoms including headache, pharyngitis, gastroenteritis, and muscle pains. Adenovirus has a very similar presentation, but with the addition of conjunctivitis. Parvovirus B19 has many other unique manifestations including rashes, arthralgias, and anemia due to a decrease in erythropoiesis. This patient did not manifest any of these symptoms. Other infections like B burgdorferi (causative agent in Lyme disease) have also been reported. Lyme myocarditis is less likely in this patient, especially considering the absence of any woodland exposure, tick bites, rashes concerning for erythema migrans, and ECG abnormalities. 7 Drug-induced myocarditis is another well-described cause of myocarditis with varying pathophysiologic mechanisms ranging from toxic effects of the drugs themselves to a hypersensitivity reaction to the medication. 5 Following initiation of a new medicine, clinicians should always be cognizant of potential adverse effects. Clozapine's adverse effect of agranulocytosis is well known, but its cardiotoxicity leading to myocarditis is less familiar, although still described in the literature. It has been suggested that approximately 1% of patients that begin taking clozapine experience myocarditis, especially within the first few months of commencing the medication. 8 In this particular patient, in the absence of any specific infectious symptoms, no known sick contacts, and high suspicion for a known drug effect, clozapine was deemed the likely offending agent causing his myocarditis.
Which
Following diagnosis, clozapine was promptly withheld. The psychiatric service was consulted for input of alternative therapy.
3. Which one of the following is the best treatment for this patient? a. Prednisone and azathioprine b. High-dose intravenous immunoglobulin (IVIG) c. Guideline-directed medical heart failure therapy d. Placement of an implantable cardioverterdefibrillator (ICD) e. Low-dose daily aspirin Although pharmacological therapy is often initiated for its clinical benefits, there is almost always the potential for unwanted adverse effects that contradict therapeutic intentions. The clinical features of our patient scenario are consistent with toxic myocarditis secondary to clozapine. Considering this probability, it is imperative to tailor further therapy to the suspected cause in order to alleviate symptoms. Treatment with prednisone and azathioprine has shown some efficacy in randomized controlled trials but has not been validated in multicenter studies and is not the first-line therapy for nonautoimmune myocarditis. 5 High-dose IVIG functions on the presumption that it suppresses inflammation; however, no current evidence supports its use in myocarditis. In addition to exercise restriction for at least 2 years, heart failure therapy is the mainstay of therapy for acute myocarditis. 9, 10 Its benefits have been well documented in myocarditis, especially in patients with left ventricular dysfunction, as seen with our patient. This therapy includes angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, b-blockers, diuretics as needed, and potentially aldosterone antagonists. In the setting of arrhythmias, placement of an ICD in patients with acute myocarditis is controversial because the myocarditis may completely heal. 5 Temporary pacing can be used if lifethreatening arrhythmias such as thirddegree heart block are present. Because the patient did not have any evidence of arrhythmias, ICD placement was not warranted. Lastly, there is no role for aspirin, or any nonsteroidal anti-inflammatory drugs, in the current standard of care for myocarditis.
Based on consultative recommendations, our patient was treated conservatively for his clinical syndrome of heart failure. We initiated treatment with low-dose carvedilol twice daily and low-dose lisinopril daily. These medications were up-titrated slowly as patient's heart rate and blood pressure would allow. To definitively diagnose myocarditis, the gold standard is endomyocardial biopsy. Unfortunately, this test is invasive and is best utilized only under certain clinical scenariosdin particular, new-onset fulminant heart failure with hemodynamic compromise in which the cause cannot be explained or heart failure that is not appropriately responding to usual therapy 11 and suspicion for giant cell myocarditis is present. Given the lack of clinical suspicion for giant cell myocarditis and the absence of hemodynamic comprise, biopsy was not pursued. In clinical practice, and when available, cardiac MRI is the test of choice for the diagnosis of myocarditis, with both T1-and T2-weighted changes increasing the specificity of the test for myocardial inflammation. Cardiac catheterization and cardiac CT angiography are useful to exclude severe coronary artery disease but are not specific to the diagnosis of myocardial disease. Exercise echocardiography in this patient would provide insight into exercise hemodynamics but would not be diagnostic and may in fact be harmful if a clinical suspicion for active myocarditis exists.
Cardiac MRI revealed abnormal delayed enhancement involving the right ventricular outflow tract and the right ventricular free wall, as well as patchy involvement of the epicardium and mid myocardium of the lateral left ventricular wall. After excluding other causes of myocarditis and considering the temporal relationship of symptoms to medication changes, the consensus was that the new myocardial disease was secondary to clozapine-induced myocarditis. At this time, no definitive guidelines for scheduled outpatient surveillance in patients with myocarditis have been published. This lack of guidelines is largely due to the variable natural history of myocarditis, complete resolution in some patients, and sudden cardiac death in others. Specific recommendations for surveillance have been proposed. They were developed on the basis of the clinical manifestations of the individual patient's myocarditis and predicted prognosis, in part based on left ventricular predictors of recovery in myocarditis including use of heart failure therapy, less late gadolinium enhancement on MRI, and higher baseline left ventricular function at the time of myocarditis diagnosis. 10 In high-risk patients, including those with acute hemodynamic compromise, conduction abnormalities, and extensive left ventricular derangements seen on MRI, it is recommended that the patient should initially follow up in less than a month, then at least 2 more times by the 12-month mark, followed by annual visits for life. Low-risk patients, including those solely presenting with chest pain, normal left ventricular function, and no arrhythmias, can be followed up in 1 months' time to assure stability of disease, with expected completion of follow-up in 2 years' time. Individuals in between these 2 categories, like our patient, should plan to follow up in 3 months, then at 6 and 12 months, and eventually annually thereafter (unless a sudden change in their clinical status develops, necessitating closer surveillance).
The cardiology service recommended continuation of carvedilol, lisinopril, and exercise restriction. Additionally, they arranged for follow-up in 3 months, with plans for an MRI and measurement of inflammatory markers before the appointment. Repeat TTE obtained several weeks after dismissal revealed recovered left ventricular function with an estimated ejection fraction of 55%.
DISCUSSION
Myocarditis is defined as inflammation of the myocardium. There have been specific ways to define it in the past using pathologic, immunologic, and immunohistochemical criteria. 5, 9, 10 The limitation associated with this definition is the requirement for an endomyocardial biopsy, which has gradually fallen out of favor, unless warranted by compelling clinical circumstances. Complicating this scenario more is the often heterogeneous presentation and clinical course of myocarditis. Although it typically presents with acute-onset heart failure symptoms, arrhythmia, and/or chest pain, myocarditis should only be suspected after ruling out other cardiac etiologies, specifically ACS. 4 Although some etiologies of myocarditis remain undiagnosed, a large range of infectious, autoimmune, and toxic causes currently exist. This case demonstrated a toxic etiology of myocarditis caused by the medication clozapine. 5 Described in the literature, the exact mechanism for the cause is unknown, although it is potentially thought to be due to an IgE-mediated hypersensitivity reaction (based on endomyocardial biopsies showing eosinophilic infiltrate) or elevated plasma norepinephrine levels (a consistent effect of clozapine). 12 A retrospective review of the known clozapine myocarditis cases found that with removal of clozapine and myocarditis treatment, at least 50% of patients recover from the disease. 8 Other drugs commonly implicated in myocarditis include illicit medications (amphetamines, cocaine), antibiotics (penicillin, tetracycline), sulfonamides, and antiseizure medications (phenytoin).
Diagnosis of myocarditis can be definitively established with invasive endomyocardial biopsy. 5, 9, 10 Fortunately, with the advent of cardiac MRI, biopsy is not required unless there is no response to treatment or a more fulminant myocarditis process like giant cell myocarditis is suspected. 10 With the use of T2-weighted imaging and postcontrast delayed imaging protocols in cardiac MRI, myocarditis can be diagnosed with a sensitivity of 84%, specificity of 74%, and diagnostic accuracy of 79%. 13 Unfortunately, because MRI requires a patient to lay flat for a long period of time, it may not be easily performed in every patient.
As previously described, most therapy for myocarditis, if hemodynamically stable, should follow the current heart failure guidelines. In addition, exercise restriction is recommended for at least 6 months following the diagnosis. If an offending agent is suspected, such as in our case, it should be discontinued. Immunomodulatory therapy, such as antivirals and IVIG, have no validated role in therapy as of yet. 9, 10 New emerging data show that there may be a role for the combination of prednisone and azathioprine, but this hypothesis needs to be confirmed in multicenter studies. 5 Lastly, patients with a confirmed diagnosis of myocarditis must be scheduled for follow-up in the outpatient setting at intervals corresponding to the severity of their initial presentation and predicted prognosis. 10 Initial follow-up should occur within the first few months, or sooner, and include at least ECG and TTE at each appointment, and in some instances cardiac MRI.
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CONCLUSION
Myocarditis is a heterogeneous disease of exclusion with nonspecific symptoms that should be considered after other potential life-threatening etiologies have been ruled out. Many etiologies of myocarditis exist, making the diagnosis even more challenging. Ideally, if MRI can be performed, it can greatly aid in diagnosis. In hemodynamically stable patients with reduced left ventricular function, guideline-directed medical therapy for heart failure should be administered. Further outpatient surveillance should then be performed depending on the initial presentation of the myocarditis.
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